Last reviewed · How we verify
NCT05794204
RMP-A03 Ocular Suspension in Patients With Pterygium
Phase 2 trial testing RMP-A03 - Dose 1 in Pterygium in 77 participants. Completed in 12 January 2024.
12 January 2024
Quick facts
| Lead sponsor | Suzhou Raymon Pharmaceuticals Company, Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 77 |
| Start date | 9 June 2023 |
| Primary completion | 12 January 2024 |
| Estimated completion | 12 January 2024 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- RMP-A03 - Dose 1 — full drug profile →
- RMP-A03 - Dose 2
- RMP-A03 Placebo — full drug profile →
Conditions studied
- Pterygium — all drugs for Pterygium →
Sponsor
Suzhou Raymon Pharmaceuticals Company, Ltd. — full company profile →
Who can join
18 and older, any sex, with Pterygium. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05794204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pterygium
Currently open trials in the same condition.
- NCT06402643 — Comparison of Recurrence Between Mini-SLET and Limbal-Conjunctival Autograft Techniques in Primary Pterygium · NA · recruiting
- NCT05456425 — A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05794204 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Raymon Pharmaceuticals Company, Ltd.
- Last refreshed: 6 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing